OTCMKTS:SIGY Sigyn Therapeutics (SIGY) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free SIGY Stock Alerts $5.25 -0.25 (-4.55%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$5.25▼$5.2550-Day Range$4.50▼$6.3452-Week Range$2.08▼$12.80Volume200 shsAverage Volume93 shsMarket Capitalization$6.41 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Sigyn Therapeutics alerts: Email Address Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... About Sigyn Therapeutics Stock (OTCMKTS:SIGY)Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.Read More SIGY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SIGY Stock News HeadlinesMarch 5, 2024 | finance.yahoo.comSigyn Therapeutics™ to Present at Tomorrow’s Emerging Growth ConferenceMarch 5, 2024 | finance.yahoo.comSigyn Therapeutics to Present at Tomorrow's Emerging Growth ConferenceMay 3, 2024 | StockEarnings (Ad)The AI stock to buy right nowThere are about 350,000 large corporations worldwide. Can you see the potential for this AI company to grow like crazy?March 5, 2024 | globenewswire.comSigyn Therapeutics™ to Present at Tomorrow's Emerging Growth ConferenceFebruary 21, 2024 | globenewswire.comSigyn Therapeutics™ Announces Filing of 2023 Annual Report on SEC Form 10-KFebruary 3, 2024 | finanznachrichten.deSigyn Therapeutics, Inc.: Sigyn Therapeutics Completes Reverse Stock SplitFebruary 2, 2024 | msn.comSigyn Therapeutics Announces 1-for-40 Reverse Stock SplitFebruary 1, 2024 | finance.yahoo.comSigyn Therapeutics Completes Reverse Stock SplitMay 3, 2024 | StockEarnings (Ad)The AI stock to buy right nowThere are about 350,000 large corporations worldwide. Can you see the potential for this AI company to grow like crazy?January 30, 2024 | finanznachrichten.deSigyn Therapeutics, Inc.: Sigyn Therapeutics Announces Reverse Stock SplitJanuary 30, 2024 | finanznachrichten.deSigyn Therapeutics, Inc.: Sigyn Therapeutics Releases Letter to ShareholdersJanuary 30, 2024 | markets.businessinsider.comEQS-News: Sigyn Therapeutics Announces Reverse Stock SplitJanuary 30, 2024 | finance.yahoo.comSigyn Therapeutics Announces Reverse Stock SplitJanuary 4, 2024 | finance.yahoo.comSigyn Therapeutics Releases Letter to ShareholdersDecember 12, 2023 | finanznachrichten.deSigyn Therapeutics, Inc.: Sigyn Therapeutics Announces Appointment of Jerry DeCiccio as Chief Financial OfficerDecember 12, 2023 | msn.comSigyn Therapeutics appoints Jerry DeCiccio as finance chiefDecember 12, 2023 | finance.yahoo.comSigyn Therapeutics Announces Appointment of Jerry DeCiccio as Chief Financial OfficerNovember 15, 2023 | finanznachrichten.deSigyn Therapeutics, Inc.: Sigyn Therapeutics Reports Third Quarter 2023 Financial ResultsNovember 15, 2023 | msn.comSigyn Therapeutics Inc GAAP EPS of -$0.02November 14, 2023 | finance.yahoo.comSigyn Therapeutics Reports Third Quarter 2023 Financial ResultsOctober 4, 2023 | finance.yahoo.comSigyn Therapeutics™ Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment ToxicitySeptember 15, 2023 | finance.yahoo.comSigyn Therapeutics to Present at Today’s Emerging Growth Conference and Tomorrow at the National Investment Bankers Association ConferenceJune 23, 2023 | morningstar.comRelay Therapeutics Inc Ordinary SharesMay 22, 2023 | fool.comBeam Therapeutics (NASDAQ: BEAM)May 17, 2023 | finance.yahoo.comSigyn Therapeutics Discloses “DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES” Patent Submission and Related ImmunePrep™ Trademark ApplicationMay 16, 2023 | finanznachrichten.deSigyn Therapeutics, Inc.: Sigyn Therapeutics Reports First Quarter 2023 Financial ResultsMay 16, 2023 | finance.yahoo.comSigyn Therapeutics Reports First Quarter 2023 Financial ResultsSee More Headlines Receive SIGY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sigyn Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolOTCMKTS:SIGY CUSIPN/A CIK1642159 Webwww.sigyntherapeutics.com Phone(619) 353-0800FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,150,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-958.06% Debt Debt-to-Equity RatioN/A Current Ratio0.03 Quick Ratio0.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.80) per share Price / Book-1.88Miscellaneous Outstanding Shares1,220,000Free Float264,000Market Cap$6.41 million OptionableNot Optionable Beta-1.66 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. James A. Joyce Ph.D. (Age 62)Co-founder, Chairman & CEO Inventor Comp: $486.04kMr. Craig P. Roberts (Age 70)Co-founder, CTO & Director Comp: $256.46kMr. Gerald DeCiccio CPAM.B.A., Chief Financial OfficerMs. Charlene R. OwenDirector of OperationsDr. Annette Marleau Ph.D. (Age 49)Chief Scientific Officer Key CompetitorsPlus TherapeuticsNASDAQ:PSTVVapothermNYSE:VAPOVivos TherapeuticsNASDAQ:VVOSIntelligent Bio SolutionsNASDAQ:INBSAvingerNASDAQ:AVGRView All Competitors SIGY Stock Analysis - Frequently Asked Questions How have SIGY shares performed in 2024? Sigyn Therapeutics' stock was trading at $0.1183 at the start of the year. Since then, SIGY stock has increased by 4,339.7% and is now trading at $5.25. View the best growth stocks for 2024 here. How do I buy shares of Sigyn Therapeutics? Shares of SIGY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SIGY) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersThe AI stock to buy right nowStockEarningsCould Your Accounts Be Frozen?Allegiance GoldUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap Profits$5,000 Gold?Stansberry ResearchBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sigyn Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
